News

「Discovery & Development Europe 2026(15–16 June)」Exhibition Information

SPERA PHARMA is pleased to announce our participation in Discovery & Development Europe, taking place at Estrel Congress Centre, Berlin, Germany, from June 15 to 16, 2026. In addition, Atsushi Kaga from ou...

SPERA PHARMA will exhibit at INTERPHEX 2026, held at Makuhari Messe from May 20 to 22, 2026.   ★INTERPHEX 2026★    Date   : May 20-22, 2026    Venue: Booth 18-40, Makuhari Messe, Chiba, ...

How We Overcame API Shortages and Tight Development Timelines in Early Clinical Stages - Xcelodose® Utilization Case Studies

These case studies showcase how, through the combination of the Xcelodose® system and SPERA PHARMA’s expertise, we were able to meet project requirements even with limited API quantities and tight timelines. ...

Structure determination is one of the most critical challenges in advancing drug discovery research and process development. Conducting this process swiftly and accurately allows us to obtain multiple opinions...

「CPHI Japan 2026(April 21-23)」Exhibition Information

SPERA PHARMA will exhibit at CPHI Japan 2026, held at Tokyo Big Sight from April 21 to 23, 2026. ★CPHI Japan 2026★    Date   : April 21-23, 2026    Venue: Booth 1A-41, East Hall 5, Tokyo Big Sig...

[Research Achievement] Research result on a novel [2+2+1] radical annulation reaction enabled by 3D ED/MicroED have been published (Joint Research with Meiji Pharmaceutical University)

A co-authored research paper by Keiyo Nakai and Mitsuhisa Yamano (SPERA PHARMA), together with Professor Nozomi Saito and Professor Masanori Tayu of Meiji Pharmaceutical University, has been published in The J...

MORE

now loading.

page top